Although the list of cell and gene therapies is growing, prices remain high. Now developers are working on a road map to streamline production and drop costs
Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities
The pandemic is serving as an accelerated lesson in the possibilities of digital engagement. Now pharma must work out how to harness its full potential
Pharma’s gradual evolution into digital-first commercial has become urgent in the COVID-19 world. A comprehensive multi-channel approach including the use of digital tools to enhance customer engagement will transform pharma sales.
Rare disease patients are organising like never before, turning up the publicity volume and becoming ever more active in driving cures in the lab and even the boardroom
Breakthrough CGT therapies are coming thick and fast, now pharma must work on multiple fronts to educate non-specialist stakeholders about their exciting possibilities